Next |
home / stock / eyeg / eyeg message board
Subject | By | Source | When |
---|---|---|---|
KPRX is the new symbol. Have traded | PennyStockTrader2 | investorshub | 11/16/2021 12:37:45 AM |
Was starting to look at getting back in | BooDog | investorshub | 10/22/2021 4:56:46 PM |
Looking good. 20dma crossing the 50dma. 200 | BooDog | investorshub | 10/07/2021 3:32:50 PM |
STRONG BUY $11 TARGET | BooDog | investorshub | 10/05/2021 10:54:48 AM |
1.85 looks good to me. $$$ boogie | BooDog | investorshub | 10/04/2021 9:40:31 PM |
Rough day out there today for the markets. | BooDog | investorshub | 10/04/2021 4:10:14 PM |
going the wronge way buying dip here | peterus | investorshub | 10/04/2021 2:29:31 PM |
yup small float | peterus | investorshub | 10/04/2021 1:41:54 PM |
This could get interesting. | BooDog | investorshub | 10/04/2021 1:35:32 PM |
Gap up to fill $2.19 anytime now. | Corey3055 | investorshub | 09/14/2021 2:24:49 PM |
??? | Mygolfballs | investorshub | 08/10/2021 2:24:17 PM |
More! Then acquisition. | JSwy17 | investorshub | 08/10/2021 12:34:29 AM |
well I couldnt help myself and bought some | PennyStockTrader2 | investorshub | 08/05/2021 3:09:20 AM |
Sold everything on the pre-market at 6.40 the | PennyStockTrader2 | investorshub | 08/01/2021 9:20:24 PM |
WOW $EYEG YUUUUGE HITS!! | Chivito | investorshub | 07/27/2021 2:24:57 PM |
$HUGE NEWS! MERGER! | MonstaGains | investorshub | 07/27/2021 1:51:38 PM |
Eyegate has been good to me ever time, | PennyStockTrader2 | investorshub | 12/21/2020 11:34:03 PM |
* * $EYEG Video Chart 12-21-2020 * * | ClayTrader | investorshub | 12/21/2020 9:50:38 PM |
$EYEG is screaming for the top after announcing | AlphaStockNews | investorshub | 12/21/2020 3:18:01 PM |
Out $EYEG $7.75 congrats all. I would have | cjstocksup | investorshub | 12/21/2020 2:17:53 PM |
News, Short Squeeze, Breakout and More Instantly...
Eyegate Pharmaceuticals Inc. Company Name:
EYEG Stock Symbol:
NASDAQ Market:
LONDON, UK / ACCESSWIRE / December 9, 2022 / Kazia Therapeutics has announced the publication of pre-clinical data for its second pipeline asset, EVT801 in the journal Cancer Research Communications. The research was conducted by licensing partner Evotec and was the key driver for Kazia in-licen...
LONDON, UK / ACCESSWIRE / December 7, 2022 / With its H123 interim results, ReNeuron highlighted progress across its proprietary exosome platform, CustomEx. The company reported H123 revenues of £438k (H122: £58k), primarily related to income associated with a £320k payment from F...
WALTHAM, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announc...